SGLT-2 inhibitors appear to offer a protective effect against heart failure in patients with type 2 diabetes mellitus, independent of gender, age, and HbA1c levels, pointing towards the potential of SGLT-2 inhibitors in managing heart failure risk in this population. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.